BRPI0809996B8 - compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas - Google Patents
compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticasInfo
- Publication number
- BRPI0809996B8 BRPI0809996B8 BRPI0809996A BRPI0809996A BRPI0809996B8 BR PI0809996 B8 BRPI0809996 B8 BR PI0809996B8 BR PI0809996 A BRPI0809996 A BR PI0809996A BR PI0809996 A BRPI0809996 A BR PI0809996A BR PI0809996 B8 BRPI0809996 B8 BR PI0809996B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- alopecia
- diabetes
- stroke
- viral
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 201000004384 Alopecia Diseases 0.000 title abstract 2
- 208000006011 Stroke Diseases 0.000 title abstract 2
- 231100000360 alopecia Toxicity 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000021245 head disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
Abstract
compostos. a presente invenção refere-se a compostos de fórmula (i) em que: r1 e r2 são cada qual independentemente h, alquila ou haloalquila r3 e r4 são cada qual independentemente h, haloalquila ou arila; r5 é alquila ou cicloalquilaquila ou cicloalqui-alquila cada das quais pode ser opcionalmente substituída com um ou mais grupos oh, r6 é selecionado a partir de ciclopropilamino, ciclopropilmetilsmino, ciclobutilamino, ciclobutilmetialamino e fórmula (a) em que um dentre x,y,e z é n e os restantes saõ cr9, r7, r8 e cada são independentemente h alquila ou haloalquila, em que pelo menos um dentre r7, r8, e cada r9 é diferente de h.um outro aspectro da invenção refere-se ás composições farmacêuticas que compreendem compostos de fórmula (i) e o uso dos referidos compostos no tratamento de distúrbios proliferativos distúrbios virais, acidente vascular cerebral, alopecia, disturbios dos cns, distúrbios neurodegenerativos, ou diabetes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92189707P | 2007-04-04 | 2007-04-04 | |
| GBGB0706632.7A GB0706632D0 (en) | 2007-04-04 | 2007-04-04 | New purine derivatives |
| PCT/GB2008/001173 WO2008122767A2 (en) | 2007-04-04 | 2008-04-02 | 2, 6, 9-substituted purine derivatives having anti proliferative properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0809996A2 BRPI0809996A2 (pt) | 2014-10-14 |
| BRPI0809996B1 BRPI0809996B1 (pt) | 2019-09-03 |
| BRPI0809996B8 true BRPI0809996B8 (pt) | 2021-05-25 |
Family
ID=38090893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0809996A BRPI0809996B8 (pt) | 2007-04-04 | 2008-04-02 | compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8592581B2 (pt) |
| EP (1) | EP2139893B1 (pt) |
| JP (1) | JP5466145B2 (pt) |
| CN (1) | CN101679434B (pt) |
| AU (1) | AU2008235361B2 (pt) |
| BR (1) | BRPI0809996B8 (pt) |
| CA (1) | CA2681529C (pt) |
| ES (1) | ES2427845T3 (pt) |
| GB (1) | GB0706632D0 (pt) |
| MX (1) | MX2009010660A (pt) |
| PL (1) | PL2139893T3 (pt) |
| RU (1) | RU2461559C2 (pt) |
| WO (1) | WO2008122767A2 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| GB0903346D0 (en) | 2009-02-27 | 2009-04-08 | Cambridge Advanced Tech | Transgenic Plants |
| GB201001075D0 (en) * | 2010-01-22 | 2010-03-10 | Cyclacel Ltd | Crystalline forms |
| DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
| EP4115882A1 (en) | 2015-01-16 | 2023-01-11 | The General Hospital Corporation | Compounds for improving mrna splicing |
| WO2017146253A1 (ja) | 2016-02-26 | 2017-08-31 | 公益財団法人がん研究会 | Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系 |
| KR102524773B1 (ko) * | 2017-01-26 | 2023-04-21 | 싸이클라셀 리미티드 | 퓨린 유도체의 제조 방법 |
| EP3388432A1 (en) | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
| IL282737B2 (en) | 2018-11-01 | 2025-05-01 | Syros Pharmaceuticals Inc | Cyclin-dependent kinase 7 (CDK7) inhibitors |
| RU2754441C2 (ru) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
| GB202000901D0 (en) | 2020-01-22 | 2020-03-04 | Cyclacel Ltd | Process |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
| TW202440578A (zh) | 2022-12-16 | 2024-10-16 | 瑞典商阿斯特捷利康公司 | ２，６，９－三取代嘌呤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| DE60023268T2 (de) * | 1999-02-01 | 2006-06-01 | CV Therapeutics, Inc., Palo Alto | INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha |
| US6627633B2 (en) * | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
| JP4381804B2 (ja) * | 2001-06-27 | 2009-12-09 | サイクラセル リミテッド | ２，６，９−置換プリン誘導体及び増殖性疾患の治療におけるその使用 |
| US6812232B2 (en) * | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
| US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| US20030229105A1 (en) * | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| EP1590341B1 (en) * | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| ES2403558T3 (es) * | 2004-08-27 | 2013-05-20 | Cyclacel Limited | Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias |
| GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
-
2007
- 2007-04-04 GB GBGB0706632.7A patent/GB0706632D0/en not_active Ceased
-
2008
- 2008-04-02 CA CA2681529A patent/CA2681529C/en active Active
- 2008-04-02 RU RU2009140753/04A patent/RU2461559C2/ru active
- 2008-04-02 CN CN2008800189406A patent/CN101679434B/zh active Active
- 2008-04-02 MX MX2009010660A patent/MX2009010660A/es active IP Right Grant
- 2008-04-02 EP EP08718980.9A patent/EP2139893B1/en active Active
- 2008-04-02 AU AU2008235361A patent/AU2008235361B2/en not_active Ceased
- 2008-04-02 WO PCT/GB2008/001173 patent/WO2008122767A2/en not_active Ceased
- 2008-04-02 BR BRPI0809996A patent/BRPI0809996B8/pt active IP Right Grant
- 2008-04-02 PL PL08718980T patent/PL2139893T3/pl unknown
- 2008-04-02 ES ES08718980T patent/ES2427845T3/es active Active
- 2008-04-02 JP JP2010501585A patent/JP5466145B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-05 US US12/573,337 patent/US8592581B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009140753A (ru) | 2011-05-10 |
| MX2009010660A (es) | 2010-02-17 |
| AU2008235361A1 (en) | 2008-10-16 |
| ES2427845T3 (es) | 2013-11-04 |
| BRPI0809996B1 (pt) | 2019-09-03 |
| BRPI0809996A2 (pt) | 2014-10-14 |
| RU2461559C2 (ru) | 2012-09-20 |
| US20100093769A1 (en) | 2010-04-15 |
| US8592581B2 (en) | 2013-11-26 |
| WO2008122767A3 (en) | 2008-12-31 |
| WO2008122767A2 (en) | 2008-10-16 |
| HK1139939A1 (en) | 2010-09-30 |
| EP2139893A2 (en) | 2010-01-06 |
| PL2139893T3 (pl) | 2013-11-29 |
| AU2008235361B2 (en) | 2013-02-14 |
| JP5466145B2 (ja) | 2014-04-09 |
| GB0706632D0 (en) | 2007-05-16 |
| EP2139893B1 (en) | 2013-06-19 |
| CN101679434B (zh) | 2013-09-25 |
| CA2681529A1 (en) | 2008-10-16 |
| JP2010523534A (ja) | 2010-07-15 |
| CA2681529C (en) | 2015-06-30 |
| CN101679434A (zh) | 2010-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0809996B8 (pt) | compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas | |
| BR112014023384A2 (pt) | inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos | |
| BR112022021962A2 (pt) | Imidazopiridazinas como moduladores de il-17 | |
| BRPI0811280B8 (pt) | compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| CL2008002271A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o su sal farmaceutica; proceso de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno del sistema nervioso central tal como alzheimer, demencia senil, parkinson. | |
| BR112013020620A2 (pt) | análogos de ácido 4-hidroxibutírico | |
| BR112015014333A2 (pt) | compostos antivirais | |
| BR112015020772A2 (pt) | compostos de pirimidina e piridina e seu uso | |
| BRPI0407976A (pt) | tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6 | |
| BR112014012217A2 (pt) | derivados de 2-fenilaminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| BR112015008717A2 (pt) | composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii | |
| BRPI0709773B8 (pt) | derivados de malonamida, processo de produção do mesmo, medicamento, e seus usos como inibidores de gama-secretase no tratamento do mal de alzheimer | |
| BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
| EA201171172A1 (ru) | Применение в терапии производных хиназолиндиона | |
| BRPI0707401B8 (pt) | compostos inibidores de cinase, composição farmacêutica, processo para a preparação e usos dos referidos compostos ou de um pró-fármaco de um composto | |
| BR112015022849A2 (pt) | sais de adição de base de nitroxolina e usos dos mesmos | |
| ATE543799T1 (de) | Piperidinyl- und piperazinylmodulatoren von g- sekretase | |
| BR112014031969A2 (pt) | derivados de pirimidinona como agentes antimaláricos | |
| BRPI0514269A (pt) | compostos heterocìclicos como agentes farmacêuticos | |
| BR112018004719A2 (pt) | composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto | |
| CL2008003465A1 (es) | Compuestos derivados de cicloalquiloxi- y heterocicloalquiloxi- piridina, moduladores del receptor de histamina h3; composicion farmaceutica; y su uso en el tratamiento de trastornos cognitivos, del sueño y psiquiatricos, tales como demencia, enfermedad de alzheimer, deficits cognitivos, insomnio, alteraciones del sueño y depresion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM |
|
| B25G | Requested change of headquarter approved |
Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |